CAMP Stock Summary and Trading Ideas (Camp4 Therapeutics | NASDAQ:CAMP)

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.

Camp4 Therapeutics trades on the NASDAQ stock market under the symbol CAMP.

As of September 1, 2026, CAMP stock price declined to $3.87 with 31,254 million shares trading.

CAMP has a beta of 2.24, meaning it tends to be more sensitive to market movements. CAMP has a correlation of 0.04 to the broad based SPY ETF.

CAMP has a market cap of $242.73 million. This is considered a Small Cap stock.

Last quarter Camp4 Therapeutics reported $2 million in Revenue and -$.58 earnings per share. This fell short of revenue expectation by $-3,000 and missed earnings estimates by -$.36.

The top ETF exchange traded funds that CAMP belongs to (by Net Assets): VTI, IWM, IWO, VXF, VTWO.

CAMP has outperformed the market in the last year with a return of +154.6%, while the SPY ETF gained +19.6%. However, in the most recent history, CAMP shares have underperformed the stock market with its stock returning -11.8% in the last 3 month period and -22.6% for the last 2 week period, while SPY has returned +1.2% and -1.1%, respectively.

CAMP support price is $3.67 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAMP shares will trade within this expected range on the day.